Update shared on07 Aug 2025
Fair value Increased 1.60%With the consensus analyst price target unchanged at $69.44, Halozyme Therapeutics saw a modest improvement in valuation as its future P/E declined, signaling slightly enhanced earnings expectations.
What's in the News
- Halozyme raised 2025 earnings guidance, expecting total revenue of $1,275–$1,355 million (26–33% growth) and royalty revenue of $825–$860 million (44–51% growth) over 2024.
- The company completed repurchasing 10,452,267 shares (8.38% of shares outstanding) for $553.49 million under its buyback program.
- Halozyme was added to the Russell 1000, Russell 1000 Growth, Russell 1000 Dynamic, Russell Midcap, Russell Midcap Growth, and Russell Midcap Growth Benchmark indexes, while being removed from the Russell 2000, Russell 2000 Growth, Russell 2000 Dynamic, Russell 2000 Defensive, and Russell 2000 Growth-Defensive indexes.
- Argenx received European Commission approval for VYVGART® (efgartigimod alfa) with Halozyme’s ENHANZE® technology for adult CIDP, marking the first novel mechanism for the condition in over 30 years.
Valuation Changes
Summary of Valuation Changes for Halozyme Therapeutics
- The Consensus Analyst Price Target remained effectively unchanged, at $69.44.
- The Future P/E for Halozyme Therapeutics has fallen slightly from 8.03x to 7.63x.
- The Discount Rate for Halozyme Therapeutics remained effectively unchanged, moving only marginally from 6.91% to 6.93%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.